DermaSensor

11/12/2025

Technology is transforming how primary care physicians evaluate skin cancer risk. 💡

Dr. Bret Kueber shares how DermaSensor allows him to quickly assess suspicious lesions during routine exams — with no disruption to workflow and immediate results that patients appreciate.

Simple. Non-invasive. Backed by AI.

👇 Watch Dr. Kueber’s experience and hear why he recommends DermaSensor.

11/05/2025

Two newly published studies in JAAD International and JCAD validate the consistent performance of DermaSensor’s FDA cleared, AI-powered device and its ability to improve physicians’ melanoma detection. The studies found:

- Melanoma detection increased from 70.2% to 79.1%, decreasing missed melanoma from 29.8% to 20.9%.
- 91.5% of the study physicians agreed the device added value to their clinical care.
- 75% agreed it would help detect more skin cancers.
- 71% reported increased confidence in evaluating skin lesions.

Now in use by hundreds of physicians, DermaSensor continues to empower clinicians with rapid, objective lesion assessments — helping bridge gaps in dermatology access and improve patient outcomes.

📄 Read the full press release: https://hubs.li/Q03RVxQj0

10/29/2025

Every year, millions of Americans are diagnosed with skin cancer - but most cases can be prevented or treated when caught early.

DermaSensor helps physicians non-invasively assess suspicious skin lesions during routine visits, so patients get the reassurance or next steps they need right away.

💙 Find a DermaSensor provider near you: https://hubs.li/Q03QQt_d0

10/23/2025

🏆 DermaSensor has been named “Best in Class – Clinical Diagnostic Device” at the 2025 Digital Health Hub Awards at ! This recognition celebrates real-world innovation in healthcare and we’re proud to empower primary care with real-time, non-invasive skin cancer detection.

From AI-driven breakthroughs to digital health pioneers, we’re honored to stand alongside inspiring leaders shaping the future of care.

10/17/2025

Evaluating suspicious skin lesions remains a challenge — visual exams are subjective, and dermatology training varies widely among clinicians.

DermaSensor is addressing this challenge with its FDA-cleared, AI-powered spectroscopy device that provides fast, objective insights to assess skin cancer risk and support clinical decision-making in real time.

👉 Learn how DermaSensor is advising skin cancer detection https://hubs.li/Q03P5M9f0

10/10/2025

What a great week FMX2025! 🙌

The excitement and positive feedback we received were incredible. It’s clear that DermaSensor is helping primary care providers bring skin cancer detection directly into their offices.

A special thank you to Dr. Nate Falk, MD, MBA, CPE, FAAFP, for joining our team and sharing his first-hand experience using DermaSensor in practice - and to all the attendees who stopped by and made this such a great event.

Until next year, FMX! 👋

To learn more about our technology and reimbursement options, visit: https://hubs.li/Q03N8QZh0

10/09/2025

This week, our CEO, Cody Simmons, joined medtech leaders at AdvaMed’s MedTech Conference in San Diego to share insights on innovation and how new technologies reach patients faster.

This year’s event marked AdvaMed’s 50th anniversary, uniting thousands of attendees and companies from around the world to explore how medtech continues to shape the future of healthcare.

We appreciate the opportunity to be part of these conversations that foster collaboration and drive innovation across the industry.

👉 Learn more about our technology at https://hubs.li/Q03MZHxS0

10/02/2025

🚀 Big news from DermaSensor! We’ve raised $16 million in Series B funding, bringing our total to $43 million — fueling the expansion of our FDA cleared, handheld skin cancer detection device.

Since launching in mid-2024, we've surpassed 20,000 lesions scanned with an incredible 117% quarterly growth rate, helping frontline physicians detect cancer earlier and more accurately.

Featured in publications like Nature and media outlets like TIME’s Best Inventions of 2024, our AI-powered optical spectroscopy device is the first and only of its kind approved for primary care use in the U.S.

We're proud to be transforming skin cancer detection and excited for what’s next. Thank you to our investors — including Pier 70 Ventures, Kern Venture Group, GenHenn Capital, and more — for believing in our mission.

👉Read more: https://hubs.li/Q03LW3cf0

10/01/2025

💯 Grateful to sponsor this year’s Private Physicians Alliance Annual Meeting 2025!

DermaSensor joined this exclusive community of concierge physicians to share how our FDA-cleared, AI-powered device supports skin cancer risk assessments right at the point of care.

A special thank you to Dr. Brian Hollett, MD, from Chicago-based SHIFT for leading an engaging session, where he presented how skin cancer detection with DermaSensor is seamlessly integrated into his clinical workflow, empowering concierge physicians with real-time, data-driven insights to better serve their patients.

Great conversations, inspiring peers, and a shared commitment to advancing personalized healthcare. We’re grateful to have connected with so many leaders shaping the future of medicine at PPA 2025!

09/25/2025

🌟 Proud Moment for DermaSensor 🌟

We’re honored to be recognized as Best Skin Cancer Detection Technology Company 2025 – USA by Global Health & Pharma.

This recognition reflects our mission to help address two of healthcare’s biggest challenges in skin cancer detection:
1️⃣ The difficulty general practitioners face in identifying skin cancers among millions of lesions.
2️⃣ The long wait times patients endure to see a dermatologist.

At DermaSensor, we’re addressing both. 💡
✔️ Empowering healthcare professionals with data-driven breakthrough technology.
✔️ Enabling real-time lesion assessments in primary care — supporting timely referrals and better outcomes.
✔️ Driving sustained innovation, certification, and progress to strengthen frontline healthcare.

Together, we’re shaping the future of early skin cancer risk assessment. 🌍✨

09/22/2025

The first day of fall doesn’t mean we stop protecting our skin from the sun 🌞.

FOX 5 San Diego reports that over 9,500 people in the U.S. are diagnosed with skin cancer every day, and this year, more than 212,000 new cases of melanoma are expected.

In this coverage, Dr. Melanie Palm highlights the importance of daily sunscreen use and regular skin self-checks using the ABCDE rule - simple but powerful steps in prevention. It’s encouraging to see this awareness growing, reminding us how critical early detection is.

At DermaSensor, we believe technology can support both patients and clinicians in identifying risk earlier, and complement the daily prevention practices that protect us all. In our pivotal study, DermaSensor demonstrated 96% sensitivity and cut physicians’ missed skin cancers by half.

Discover more 👉 https://www.dermasensor.com/

Read the full story from FOX 5 San Diego here 👉 https://fox5sandiego.com/news/health/sun-safety-san-diego/

Dr. Melanie Palm recommends using broad-spectrum sunscreen of SPF 30 or higher daily and seeking shade during the sunniest parts of the day to protect yourself from skin cancer.

09/16/2025

Dermasensor recently hosted two Dinner Programs in FL, bringing together local clinicians to learn and exchange knowledge about the importance of early skin cancer detection.

In Tallahassee, Dr. Armand B. Cognetta Jr. shared valuable insights into the challenges physicians face in everyday practice and how new technologies like Dermasensor can support earlier detection and improve patient outcomes.
We are also grateful to Dr. Harold Rabinovitz, who led the program in Fort Lauderdale, for his expertise and for fostering meaningful discussions among peers.

These events are part of our ongoing commitment to raising awareness about how Dermasensor empowers clinicians to make more confident decisions in detecting skin cancer risk.

Thank you to all the healthcare professionals who joined us👩🏻‍⚕👨🏻‍⚕